The FDA found that data from a single Phase II study were “insufficient” to justify an accelerated approval review for ...

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

While ALTO-203 missed its depression-related endpoints, improvements in EEG biomarkers, attention and wakefulness point to ...

Calico will leverage 9MW3811’s anti-inflammatory mechanism to advance its mission of addressing aging-related diseases.

The high court found that members of a task force that determines what preventive drugs must be covered can be removed at ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...